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Abstract
Background: Biomarker discovery holds the promise for advancing personalized medicine as the biomarkers can
help match patients to optimal treatment to improve patient outcomes. However, serious concerns have been
raised because very few molecular biomarkers or signatures discovered from high dimensional array data can be
successfully validated and applied to clinical use. We propose good practice guidelines as well as a novel tool for
biomarker discovery and use breast cancer prognosis as a case study to illustrate the proposed approach.
Results: We applied the proposed approach to a publicly available breast cancer prognosis dataset and identified
small numbers of predictive markers for patient subpopulations stratified by clinical variables. Results from an
independent cross-platform validation set show that our model compares favorably to other gene signature and
clinical variable based prognostic tools. About half of the discovered candidate markers can individually achieve
very good performance, which further demonstrate the high quality of feature selection. These candidate markers
perform extremely well for young patient with estrogen receptor-positive, lymph node-negative early stage breast
cancers, suggesting a distinct subset of these patients identified by these markers is actually at high risk of
recurrence and may benefit from more aggressive treatment than cur-rent practice.
Conclusion: The results show that by following good practice guidelines, we can identify highly predictive genes
in high dimensional breast cancer array data. These predictive genes have been successfully validated using an
independent cross-platform dataset.
Introduction
The goal of biomarker discovery from high dimensional
array data is to find an individual or a set of genes (or
any other molecular variables) whose expression pattern
can predict certain phenotype or clinical outcome. Bio-
marker discovery holds the promise for advancing perso-
nalized medicine as the biomarkers can help match
patients to optimal treatment and thus improve patient
outcomes. During the past 15 years, numerous biomarkers
and gene signatures have been published in the literature.
However, few of these biomarkers can be successfully vali-
dated and applied in clinical setting, which have caused
serious concerns in biomedical research community [1].
The lack of success in biomarker discovery is mainly
due to three issues.
(1) Many published gene signatures cannot be validated
independently. This is mainly due to flawed data analysis.
For example, fail to keep completely untouched vali-
dation data or improperly use cross-validation technique
can all cause overly optimistic results being reported.
(2) Some gene signatures do not have additional clinical
benefit over known clinical variables even though the gene
signatures can be validated. For example, gene signatures
discovered from a breast cancer patient population includ-
ing both ER + and ER- patients for predicting treatment
response could probably end up approximating ER status,
an important clinical variable for predicting treatment
response.
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(3) Some gene signatures contain large numbers of
genes making them difficult to be applied in clinical set-
ting. These gene signatures may include lot of unimpor-
tant genes due to the inefficiency of the standard feature
selection techniques. For example, standard t test will
either miss or rank certain important features below
many non predictive features, if these important features
do not conform to normality.
The first two issues have been addressed in [1,2]. To
address the third issue, we developed a two-way filtering
based method to parsimoniously identify the most infor-
mative features from different types of distributions.
Our method selects features by searching for the desired
thresholds of a pair of statistics that are used to filter
features. For any pair of thresholds, the features that
satisfy both thresholds are used to build a diagonal lin-
ear discriminate analysis (DLDA) classifier [3]. When
choosing the pair of statistics, we choose one that is
more efficient at detecting strong signals such as mean
difference test, and a second that is more efficient at
controlling signal to noise ratio such as classical t-test
or Mann-Whitney U test. By varying the thresholds of
these two statistics in certain steps within their accepta-
ble ranges, we can achieve various tradeoffs and control
the size of the feature sets. The method and other sup-
porting functions are implemented in a Java based tool
called Array Data Analyzer (ADA). The detailed method
is described in [4].
Compared to standard feature selection tools, our
ADA tool has the following advantages.
(1) Because our approach does not select features
based on any single statistic or fixed tradeoff of two
statistics, it can adapt to different data and parsimo-
niously identify informative features from different dis-
tributions. Experimental result presented in [4] shows
that our approach yields much smaller models on
average when compared to other standard approaches,
yet achieving similar or better performance.
(2) By using grid-search to explore different tradeoffs
of a pair of statistics, our tool is very flexible to address
different feature selection requirements in real world
situations. For example, researchers at times are will-
ing to sacrifice performance in order to gain other
logistic properties, such as smaller numbers of features
and larger fold change. These properties enable more
tractable assays for clinical use (e.g. qPCR). By visually
examining the performance at different combinations
of cut points of the two statistics and checking the size
of feature sets, researchers can decide which feature
set would be best to use.
(3) Our Java based tool is very efficient to run even
though it conducts rigorous cross validation and
grid search to find optimal feature sets. For example,
finding an optimal gene signature from microarray
gene expression dataset with 130 samples takes
about 50 seconds on a modest laptop PC (Dell
Latitude E4300 with 2GB of RAM). (Searching
through 200 combinations of the threshold pairs of
the two statistics; using 5 times 5 fold cross validation
(CV) to measure performance of each combination).
The ADA tool has been applied to various GSK drug
discovery projects [5]. It has also been applied to the
FDA MAQC-II project [6] by the GSK data analysis
team (DAT). The GSK DAT achieved highest mean area
under the receiver operating characteristic curve (AUR-
OCC) across all 11 endpoints among the participating
DATs. Using ADA tool, we also achieved the second
place in the “The Sage Bionetworks/DREAM breast can-
cer prognosis challenge 2012” (https://sagebionetworks.
jira.com/wiki/display/BCC/Home) by simply identifying
8 genes from the provided training set.
As a case study, we performed detailed prognostic
analyses on the van de Vijver breast cancer dataset [7].
An independent cross-platform validation set TRANSBIG
[8] was then used to validate our findings. The results
show that our 20-gene signature as well as many of the
discovery individual prognostic biomarkers can achieve
comparable or better performance compared to the clini-
cal or gene signature based prognostic scores. These
discovered biomarkers have the potential to be used
in clinical settings to identify a subset of the lymph-node-
negative (Node-) and estrogen-receptor-positive (ER+)
patients who are at a higher risk of relapse.
Methods
The ADA tool
The ADA tool allows users to choose different pairs of
statistics to perform the two-way filtering. In this paper,
the default pair of non parametric statistics is used,
which are the mean difference test and the Mann-Whitney
U test. More detailed information of the ADA tool is given
in [4].
Data preprocessing
van de Vijver dataset and TRANSBIG dataset were
downloaded from the public domain. For all datasets
generated from Affymetrix platforms, if a gene intensity
value is smaller than 40, we floor it to 40. The log trans-
formed ex-pression values are used for analysis.
Scoring and classification of validation data sets using 20
gene signature
For the discovered genes that can be successfully mapped
from Agilent Hu25K platform to Affymetrix HG-U133A,
we arbitrarily decided to keep top 10 genes from each
direction (i.e., over expression ® poor prognosis and
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over expression ® good prognosis) to validate. If a gene
can be mapped to multiple probe sets of the Affymetrix
HG-U133A chip, we use the probe set that has the largest
interquartile range (IQR). To avoid bias, the scoring of
validation samples using the 20 gene signature was done
without any scaling or tuning. We simply calculated the
scores by summing up the log expression values of genes
of one direction and subtracting those of genes of the
other direction. To classify the samples into “good prog-
nosis” and “poor prognosis”, we use zero as the threshold.
Results
As a case study, we use the van de Vijver data set [7] to
discover prognostic biomarkers for various patient subsets
stratified by clinical variables. The markers discovered
from the lymph node negative patient cohort are subse-
quently evaluated using an independent cross-platform
dataset: TRANSBIG [8]. Table 1 summarizes the training
and independent validation data sets. Both data sets are
publicly available.
Model training and prognostic biomarker discovery using
van de Vijver dataset
The van de Vijver data set contains samples from 295
patients with stage I and II breast cancer. The gene
expression data was generated using Agilent Hu25K
platform. A subset of the samples was used to develop a
70-gene signature for predicting breast cancer early
relapse [9]. To make the data less noisy, we only
included patients who developed metastases in < 5 years
and those who remained disease free for > 10 years (i.e.
we removed the patients who developed metastases
between 5-10 years) in the biomarker discovery phase.
This left 78 patients who developed metastases within
5 years (poor prognosis) and 68 patients who remain
disease free for at least 10 years. Besides analyzing all
the data together, we also utilized the clinical information
(ER status and lymph node status) to create subgroups of
samples in order to search for prognostic markers within
these clinical subgroups.
By using the ADA tool, we were able to generate gene
lists of various sizes for different subgroups of patients.
After studying the gene lists, we found that many of the
predictive markers were indeed more sig-nificant in cer-
tain subgroups. For example, the ER+/lymph node+ group
harbors unique genes that are predictive of relapse. The
prognosis of this group of patients was also more predict-
able (based on nested CV results) compared to that of the
other groups. Some of the discovered genes are listed in
Table 2.
Table 1 Summary of the two data sets involved in this experiment
Data set van de Vijver TRANSBIG
Purpose in this experiment biomarker discovery biomarker validation
Microarray platform Agilent Hu25K Affymetrix HG-U133A
No. of Patients 295 198
Age <53 <61; mean = 46
ER status (pos/neg) 226/69 134/64
Lymph node (pos/neg) 144/151 0/198
Systemic treatment some none
Data location or GEO accession http://bioinformatics.nki.nl/data.php GSE7390
Table 2 Candidate markers identified from the van de Vijver data set using the proposed method
Group Sample size n (good
prog + poor prog)
Nested CV
AUROCCperformance
Feature list (high expression ® poor
prognosis)




146 (68+78) 0.73 (0.04) BIRC5, CCNB2, CENPA, TK1, CCNE2,
DKFZp762E1312, PRC1, STK15, SLC16A3, BUB1
CEGP1, SLC11A3, C4A, ZNF145,
MATN3, PGR, RAI2, DLX2
ER+ 107 (57+50) 0.76 (0.05) H1F2, COX6C, H2BFB, CCNE2, BLVRB FST, DIO3, NTN4, DLX2, MATN3,
COL3A1
Node+ 64 (30+34) 0.80 (0.06) H1F2, H2BFB, HA2FO, H2AFA, HABFB,
KFZp762E1312, H2BFS
LTF, NTN4, HML2, PER1, DMBT1,
ODZ2, WNT5A, SEMA3C





50 (26+24) 0.83 (0.06) H1F2, H2BFB, H2AFP, H2AFA, H2BFB, COX6C,
MSMB, BLVRB, , BCAS1
LTF, LAMB3, C4A, NTN4, PTPRK,
RTN1
Many genes discovered in larger groups can also be discovered in their subgroups. For example, BIRC5 can be discovered in most of the subgroups. These genes
are not listed again in subgroups unless they are more significant in the subgroups. A gene may be listed in a larger group only because it is significant in one
of its subgroups. For example, H1F2 is listed in lymph node-positive group only because it is significant in ER+/Node+ subgroup. The nested CV performance is
listed with estimated standard error.
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Independent cross platform validation using TRANSBIG
dataset
To validate the candidate biomarkers discovered from
van de Vijver data set, we download the TRANSBIG
data set (198 patients with mean age equals 46), which
is based on the Affymetrix HG-U133A platform instead
of the Agilent Hu25K platform. An original objective of
TRANSBIG data set was to validate the 70-gene signature
and it is similar to the van de Vijver data set in term of
patient age distribution - i.e., both data sets contains
young breast cancer patients. Because all patients of the
TRANSBIG data set are lymph node negative (Node-)
patients, we evaluate the candi-date biomarkers discovered
from the Node- patients.
We picked the top 20 genes from our Node- gene list
that can be mapped from Agilent Hu25K to Af-fymetrix
HG-U133A. The performance of the 20 gene-signature
as well as each of the individual gene was measured
using AUROCC based on commonly used endpoints:
time to distant metastasis(TDM) at 5 years and 10
years. Because 70% of Node- patients in the training
data belong to the subgroup Node-/ER+, in addition to
measure the performance on the whole validation sets
(consisting of Node- patients), we also measured the
performance on the Node-/ER+ subset of patients. Both
results are shown in Table 3, which also includes the
performance of two commonly used clinical scores
(Nottingham Prognostic Index Score [10] and Adjuvant!
10 year overall survival score [11]), three clinical vari-
ables (tumor grade, tumor size and age), two known
markers (ESR1 and MKI67) and three gene signatures
(16-gene signature [12], 70-gene signature [9] and
76-gene signature [13]).
From the result we can see that our 20-gene signature
performs better than other gene signature or clinical
variable based prognostic factors. Most of the 20 candi-
date genes can also be successfully validated. About half
of the 20 genes can individually achieve similar or better
performance compared to clinical variable based risk
scores, which further shows that the proposed approach
can parsimoniously select high quality features.
To further illustrate the added value of these markers
over the traditional clinical criteria, we use survival
curves to compare the 20-gene signature to the Adjvant!
10 year overall survival probability, which is based on
known clinical markers. Figure 1 plots four Kaplan-Meier
curves by dividing the TRANSBIG patients into four risk
groups based on the predictions from 20-gene signature
and the Adjvant! tool. The plots show that our 20-gene
signature is superior in predicting cancer outcome, espe-
cially for the 66 patients (33% of the 198 samples) shown
in the dotted blue survival curve where the 20-gene
signature predicts good outcome and Adjvant! predicts
poor outcome. This curve indeed traces the curve in
solid blue where the patients were predicted to have
good outcome by both classifiers.
It is also worth noting that the 20-gene signature and
the top performing genes based on the whole vali-dation
Table 3 Validation performance (AUROCC) of the
candidate biomarkers in TRANSBIG data sets
Prognostic factors TRANSBIG





202705_at(CCNB2) 0.74 0.83 0.72 0.80
209642_at(BUB1) 0.71 0.81 0.70 0.78
204962_s_at(CENPA) 0.69 0.84 0.69 0.79
203362_s_at(MAD2L1) 0.68 0.75 0.67 0.71
202095_s_at(BIRC5) 0.67 0.78 0.65 0.74
210074_at(CTSL2) 0.65 0.64 0.65 0.64
209803_s_at(PHLDA2, TSSC3) 0.61 0.62 0.59 0.61
202338_at (TK1) 0.61 0.69 0.60 0.64
204086_at(PRAME) 0.61 0.62 0.57 0.58
202218_s_at (FADSD6) 0.50 0.49 0.50 0.45
210096_at(CYP4B1) 0.71 0.78 0.70 0.74
205883_at(ZNF145) 0.69 0.75 0.66 0.71
219197_s_at(SCUBE2, CEGP1) 0.66 0.66 0.63 0.59
214053_at(ERBB4) 0.66 0.72 0.67 0.74
208305_at(PGR) 0.65 0.66 0.64 0.66
219682_s_at(TBX3) 0.63 0.66 0.63 0.65
204541_at(SEC14L2) 0.63 0.65 0.62 0.59
206091_at(MATN3) 0.61 0.55 0.61 0.56
202554_s_at(GSTM3) 0.60 0.62 0.58 0.59
219440_at(RAI2) 0.59 0.59 0.56 0.56
Our 20-gene signature 0.73 0.83 0.70 0.79
16-gene signature 0.71 0.79 0.69 0.73
70-gene signature 0.68 NA NA NA
Nottingham Prognostic Index
Score
0.67 0.68 0.66 0.66
Adjuvant! Online 10 year OS
prob.
0.66 0.64 0.67 0.63
76-gene signature 0.65 0.68 0.62 0.64
Tumor grade 0.64 0.63 0.62 0.62
Tumor Size 0.63 0.65 0.63 0.64
212021_s_at(MKI67) 0.62 0.70 0.65 0.70
205225_at (ESR1) 0.58 0.59 0.57 0.61
Age 0.53 0.47 0.52 0.51
There are two AUROCC numbers for each gene at each endpoint. The first
number is from the whole validation set with 100% Node- patients; the second
is from the Node-/ER+ subset of the validation set. The numbers in bold font
are significant at 95% confidence level. The top portion of the table contains
10 genes of one direction (over expression® poor prognosis). The middle
portion contains 10 genes of the opposite direction (over expression® good
prognosis). The bottom portion contains our signature based on all 20 genes
and other prognostic factors. The performance of the 70-gene signature for the
TRANSBIG data set is copied from [8]. The performance of the 76-gene
signature is based on binary prediction of “good prognosis” and “poor
prognosis” for each patient. Among the listed 20 genes, three genes (CENPA,
GSTM3 and CEGP1) were included in the 70-gene signatures [9] and four genes
(BIRC5, PGR, SCUBE2 and CTSL2) were included in the 16-gene signature. There
is no overlap between our 20-gene signature and the 76-gene signa-ture.
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set have even better performance when validated using
Node-/ER+ patients only. For example, for end point
TDM at 5 years, the 20-gene signature can achieve AUR-
OCC 0.83; and the genes CCNB2, BUB1, CENPA, BIRC5
and CYP4B1 can each achieve AUROCC above 0.78.
Discussion
Using the breast cancer prognosis experiment, the ADA
tool was able to effectively discover both biologically
relevant and class predictive genes. The tool has two
important features: (a) because the model performance
estimation is based on rigorous nested cross-validation,
the tool does not return any feature when the dataset
does not produce a strong signal. (b) It has a unique
iterative procedure that attempts to find all important
genes, which can be used for further analyses, such as
pathway and ontology analysis.
When doing biomarker discovery using the van de
Vijver datasets, our approach relies heavily on robust
cross validation to control over fitting rather than leaving
out an artificial validation set. This is a more efficient way
to use the relatively small number of samples - artificially
defining a small validation set is unlikely to achieve much
due to the large test data variability and reduced power of
model development in the smaller training set. However,
it is crucial that the cross-validation is done properly.
For example, the feature selection must be performed
within each run of cross validation; and the nested cross
validation is often required when evaluating model per-
formance (i.e., outer loop CV for model performance
evaluation and inner loop CV for model parameter
tuning). As we can see here, the proper cross-validation
procedures can often be quite computationally expensive.
This is one of the reasons that a simple modeling tech-
nique such as DLDA is preferred. We believe the best
way to gain better performance is through improving
performance of feature selection, rather than tuning
modeling parameters of complex models. Complicated
learning schemes can make proper cross-validation too
computational expensive to run. Without proper cross-
validation, the result can be overly optimistic. Important
guidelines for biomarker discovery are presented in
Richard Simon’s work [2].
As shown in Table 2, when sample size allows, we try to
discover biomarkers for patient subpopulations stratified
by clinical variables. This also assures us that the discov-
ered biomarkers indeed have added value over the tradi-
tional clinical variables, rather than approximating the
clinical variables.
To validate our findings from the van de Vijver data, we
used the cross-platform validation dataset TRANSBIG. In
addition to evaluate our 20-gene signature, we also evalu-
ate individual genes. By doing so, we can carry forward
those validated genes for further clinical validations. Table 3
shows that most of the 20 genes can be validated using the
TRANSBIG data set and some of the discovered candidate
genes can individually achieve similar or better perfor-
mance compared to the state-of-the-art breast cancer
prognostic tests, which suggest that our 20-gene signature
contains mostly highly predictive genes. It is very likely
Figure 1 Using Kaplan-Meier curves to compare 20-gene signature with the Adjvant! 10 year overall sur-vival score. Solid blue curve is
for the risk group that both 20-gene signature and Adjvant! predict good prognosis (n = 38); Dotted blue curve is for the risk group that
20-gene signature predicts good prognosis and Adjvant! predicts poor prognosis(n = 66); Dotted red curve is for the risk group that 20-gene
signature predicts poor prognosis and Adjvant! predicts good prognosis(n = 8); Solid red curve is for the risk group that both classifiers predict
poor prognosis (n = 86).
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that large gene signatures contain many unimportant
genes. We believe that a promising way to improve predic-
tion accuracy is to combine gene signatures with tradi-
tional clinical variables. This can be achieved by developing
gene signatures containing a small number of genes for
each clinically homogeneous subset of patients.
Table 3 also shows that for Node-/ER+ patients of
younger age (as those in TRANSBIG dataset), there are a
number of genes that can predict cancer recurrence at
high accuracy. This suggests that there is a distinct sub-
group of Node-/ER+ patients who have high risk of relapse
and should be treated more aggressively. Our 20-gene
signature is acquired from analyzing one public dataset for
one patient subpopulation (Node-). We plan to analyze
other datasets to refine this predictive gene list and
develop gene lists for other patient subpopulations.
Based on our past experience, we are confident that bio-
marker discovery can play important role in ad-vancing
personalized medicine if the study design and data analysis
is done properly. We would like to propose the following
good practice guidelines for biomarker discovery. Most of
the points have already been made in [1,2].
(1) Make sure no information leak from validation set.
If a separate validation set is available, one need to
make sure that the validation set is not used in any
way in feature filtering or model building. The same
rule also applies to cross validation.
(2) Model performance evaluation and model para-
meter tuning cannot be done using the same cross
va-lidation loop. In such case, nested cross validation
is needed (i.e., outer loop CV for model performance
evaluation and inner loop CV for model parameter
tuning).
(3) When sample size is not very large, cross validation
is a preferred validation technique.
(4) Consider patient stratification using known clinical
variables.
(5) Use simple modeling techniques. Simple models
performs well [3] and are easy to train and easy to
un-derstand.
(6) When choosing feature filtering or feature selec-
tion methods, do not automatically assume that all
va-riables are normally distributed. Many highly pre-
dictive biomarkers are far from normally distributed,
especially in cancer research [14,15].
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